HT
SAGE

Headlands Technologies’s Sage Therapeutics SAGE Stock Holding History

Headlands Technologies’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,400
Closed -$569K – 1154
2025
Q2 		$569K Buy
62,400
+57,761
+1,245% +$425K 0.07% 279
2025
Q1 		$36.9K Buy
+4,639
New +$34K ﹤0.01% 761
2024
Q3 		– Sell
-3,916
Closed -$42.5K – 1484
2024
Q2 		$42.5K Buy
3,916
+2,782
+245% +$35.6K ﹤0.01% 798
2024
Q1 		$21.3K Buy
+1,134
New +$26.2K 0.01% 896
2023
Q3 		– Sell
-2,442
Closed -$115K – 1164
2023
Q2 		$115K Buy
+2,442
New +$121K 0.04% 366

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Headlands Technologies's SAGE Position: Q3 2025 in Review

Headlands Technologies sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 62,400 shares — an estimated $569K sold.

Headlands Technologies first reported a position in SAGE in Q2 2023 and held it in 5 quarters. The position peaked at $569K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Headlands Technologies reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 62,400 Sage Therapeutics shares in Q3 2025, an estimated $569K.
  • Headlands Technologies first reported a position in Sage Therapeutics in Q2 2023 and held it in 5 quarters.
  • Headlands Technologies's Sage Therapeutics position peaked at $569K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.